BIOTRONIK BIOLUX P-I Clinical Study Published in Journal of Endovascular Therapy
Results Demonstrate Advantage of BIOTRONIK’s Passeo-18 Lux Drug-Coated Balloon Catheter for the Treatment of Superficial Femoral and Popliteal Artery Disease
BUELACH, Switzerland, March 3, 2015 – BIOTRONIK, a leading manufacturer of cardio- and endovascular medical technology, announced today that results of its BIOLUX P-I clinical study have been published in the esteemed Journal of Endovascular Therapy.BIOLUX P-I was a prospective, international, multi-center, first-in-human, randomized, controlled trial that enrolled 60 patients at five centers in Germany and Austria. The study assessed the safety and efficacy of the Passeo-18 Lux drug-coated balloon (DCB) in treating de novo and restenotic femoropopliteal lesions, and the positive results were instrumental in gaining CE mark in December 2013.Data collected at six and 12-month intervals demonstrated that patients treated with Passeo-18 Lux DCB were less likely to require treatment again.At six months, patients treated with the Passeo-18 Lux DCB had a significantly lower late lumen loss (LLL) (0.51±0.72 vs. 1.04±1.00; p=0.033) and binary restenosis rate (11.5 percent vs. 34.6 percent; p=0.048) compared to the control percutaneous transluminal angioplasty (PTA) treated patients. Correspondingly, clinically-driven target lesion revascularization (TLR) was lower in the Passeo-18 Lux DCB group at 12 months (16.0 percent vs. 52.9 percent; p=0.020) for the as-treated population. In addition, patients receiving treatment with Passeo-18 Lux showed greater improvement in Rutherford class compared to baseline (72.0 percent) versus those receiving treatment with PTA (65.2 percent).“The study has generated the positive clinical data required to prove the validity of Passeo-18 Lux as an efficacious therapy in the treatment of femoropoplieteal vessels,” commented Dr. Dierk Scheinert, primary investigator of BIOLUX P-I, University Hospital Leipzig, Germany. “With restenosis following treatment with standard PTA balloons as a significant issue, Passeo-18 Lux is proven to be an effective and durable treatment option in treating disease in the more challenging peripheral vascular anatomy.”The results of the study are being used by BIOTRONIK as a foundation to further investigate Passeo-18 Lux in real world populations, such as the BIOLUX P-III All-Comers Registry, which is currently enrolling patients in Europe and Asia Pacific. Results from BIOLUX P-I are in line with other scientific data, suggesting that treatment with DCB is a viable option and has the potential to become the standard for treating femoropopliteal arteries.“The publication of the BIOLUX P-I study is another positive milestone in displaying the Passeo-18 Lux DCB as the appropriate therapy option for lower limb arterial disease,” commented Dr. Alexander Uhl, BIOTRONIK Vice President Marketing, Vascular Intervention. “Keeping in line with BIOTRONIK’s culture of heavy investment in clinical studies, we will continue to investigate and prove its effectiveness so that patients and physicians can choose this product with the fullest confidence.”
At BIOTRONIK, patient well-being is our top priority and has been for 60 years. BIOTRONIK is a leading global medical technology company with products and services that save and improve the lives of millions suffering from heart and blood vessel diseases. Driven by a purpose to perfectly match technology with the human body, we are dedicated innovators who develop trusted cardiovascular and endovascular solutions. BIOTRONIK is headquartered in Berlin, Germany, and is represented in over 100 countries.